2 results
Approved WMOPending
To determine the test-retest variability of Compass perimetry at the edges of glaucomatous scotomas and compare it with the Humphrey Field Analyzer.
Approved WMOPending
The objectives of this are to establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg.